Luminex Posts 1 Percent Q3 Revenue Growth, Lowers Guidance Citing Reimbursement Issues | GenomeWeb

NEW YORK (GenomeWeb News) – Luminex reported after the close of the market Monday that its third quarter revenues grew 1 percent over the third quarter of 2012, but the Austin, Texas-based molecular diagnostics company lowered its revenue guidance for the year, citing US reimbursement issues.

Luminex's total revenues for the three months ended Sept. 30 were $50.8 million, compared to $50 million in the third quarter of 2012. The firm fell short of analysts' consensus expectations for revenue of $54.7 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: Neanderthal-derived DNA linked to modern ailments, and more.

Japan needs to catch up on its gene-editing research efforts, the Japan News writes.

Hundreds of people have signed an online petition calling for zero tolerance to sexual harassment in the sciences.

Jeff Huber, former Google X senior vice president, joins Grail as its CEO.